Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : STP938
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : STP938 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Thrombocythemia, Essential.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 22, 2025
Lead Product(s) : STP938
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of STP938 in Advanced Solid Tumours
Details : STP938 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 07, 2024
Lead Product(s) : STP938
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : STP938 is a first-in-class oral cancer therapeutic that specifically inhibits nucleotide synthesis and the enzyme cytidine triphosphate synthase 1 (CTPS1) in particular, originally identified as an essential gene for lymphocyte proliferation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 24, 2022
Lead Product(s) : STP938
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : STP938
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Promising pre-clinical data demonstrated strong synergistic cancer-killing potential of STP938 in combination with the emerging drugs targeting the DNA damage response pathway (e.g. ATR, WEE1, CHEK1) for solid tumours.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 28, 2022
Lead Product(s) : STP938
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : STP938
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Details : STP938 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, B-Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 18, 2022
Lead Product(s) : STP938
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : STP938
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Hadean Ventures
Deal Size : $42.3 million
Deal Type : Series B Financing
Step Pharma Raises Funds Through Series B Round to Advance Cancer Drugs
Details : The proceeds will be used to advance Step Pharma’s lead proprietary CTPS1 inhibitor, STP938, into clinical development for the treatment of T-cell malignancies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 23, 2021
Lead Product(s) : STP938
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Hadean Ventures
Deal Size : $42.3 million
Deal Type : Series B Financing